MELBOURNE, Australia & MENLO PARK, Calif.--(BUSINESS WIRE)--ChemGenex Pharmaceuticals (ASX:CXS) (NASDAQ:CXSP) announced today that positive clinical data from the first 21 patients enrolled in its ongoing phase 2/3 trial of omacetaxine mepesuccinate (formerly known as Ceflatonin®) were presented over the weekend at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia.
